`Filed: September 17, 2015
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`WOCKHARDT BIO AG
`Petitioner,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`Patent Owner
`
`________________
`
`Case IPR2015-01816
`Patent 7,895,059
`________________
`
`
`
`MANDATORY NOTICES BY JAZZ PHARMACEUTICALS, INC.
`UNDER 35 U.S.C. §§ 311-319 AND 37 C.F.R. §§ 42.8, 42.100 ET. SEQ.
`
`03387-00001/7207141.1
`
`
`
`Case IPR2015-01816
`Patent 7,895,059
`Patent Owner Mandatory Notices
`
`
`REAL PARTY-IN-INTEREST
`
`Pursuant to the requirements of 37 C.F.R. § 42.8(b)(1), the undersigned state
`
`that Jazz Pharmaceuticals, Inc. (“Jazz Pharmaceuticals”) is the real party-in-
`
`interest. Jazz Pharmaceuticals is a corporation organized and existing under the
`
`laws of the State of Delaware, having a principal place of business at 3180 Porter
`
`Drive, Palo Alto, California 94304. Jazz Pharmaceuticals owns by assignment the
`
`entire right, title, and interest in U.S. Patent No. 7,895,059 (the “’059 patent”) by
`
`virtue of an Assignment of rights from the inventors, Dayton Reardon, Patti Engle
`
`and Bob Gagne. The Assignment was recorded with the United States Patent and
`
`Trademark Office on December 22, 2010, at Reel 025604, Frame 0903.
`
`RELATED MATTERS
`
`Pursuant to 37 C.F.R. § 42.8(b)(2), the undersigned state that the ’059 patent
`
`is the subject of four, currently-pending litigations: Jazz Pharmaceuticals, Inc. v.
`
`Roxane Laboratories, Inc., 2:10-cv-6108 (D.N.J.); Jazz Pharmaceuticals, Inc. v.
`
`Amneal Pharmaceuticals LLC et al., 2:13-cv-391 (consolidated) (D.N.J.); Jazz
`
`Pharmaceuticals, Inc. v. Wockhardt Bio AG et al., 2:15-cv-5619 (D.N.J.); and Jazz
`
`Pharmaceuticals, Inc. v. Lupin Ltd. et al., 2:15-cv-6548 (D.N.J.). The litigation
`
`over the ’059 patent in Jazz Pharms., Inc. v. Roxane Labs., Inc. was stayed prior to
`
`the Petitioner filing the present IPR Petition.
`
`03387-00001/7207141.1
`
`
`
`Case IPR2015-01816
`Patent 7,895,059
`Patent Owner Mandatory Notices
`
`
`The ’059 patent is also the subject of inter partes review petitions filed by
`
`Par Pharmaceutical, Inc. (“Par”) (IPR2015-00548), Coalition for Affordable Drugs
`
`III LLC (IPR2015-1018), and Amneal Pharmaceuticals LLC (“Amneal”)
`
`(IPR2015-01810). Additionally, Petitioner has filed for inter partes review of five
`
`related patents: U.S. Patent No. 8,589,182 (IPR2015-01813); U.S. Patent No.
`
`8,457,988 (IPR2015-01814); U.S. Patent No. 7,668,730 (IPR2015-01818); U.S.
`
`Patent No. 7,765,106 (IPR2015-01815); and U.S. Patent No. 7,765,107 (IPR2015-
`
`01820).
`
`Further, Par and Amneal have together (and in certain instances, separately)
`
`filed for inter partes review of the above-identified related patents: U.S. Patent
`
`No. 8,589,182 (IPR2015-00545); U.S. Patent No. 8,457,988 (IPR2015-00551;
`
`IPR2015-01817); U.S. Patent No. 7,668,730 (IPR2015-00554); U.S. Patent No.
`
`7,765,106 (IPR2015-00546); and U.S. Patent No. 7,765,107 (IPR2015-00547).
`
`Par and Amneal have also previously filed for covered business method
`
`review of the ’059 patent (CBM2014-00149) and the above-identified related
`
`patents: U.S. Patent No. 8,589,182 (CBM2014-00153); U.S. Patent No. 8,457,988
`
`(CBM2014-00150); U.S. Patent No. 7,668,730 (CBM2014-00151); U.S. Patent
`
`No. 7,765,106 (CBM2014-00161); and U.S. Patent No. 7,765,107 (CBM2014-
`
`00175). On January 13, 2015, the Patent Trial and Appeal Board (the “Board”)
`
`03387-00001/7207141.1
`
`
`
`Case IPR2015-01816
`Patent 7,895,059
`Patent Owner Mandatory Notices
`
`
`denied institution of covered business method review of the ’059 patent in
`
`CBM2014-00149, as well as the patents involved in CBM2014-00150, CBM2014-
`
`00151 and CBM2014-00153. See CBM2014-00149 at Paper 12. On February 9,
`
`2015, the Board denied institution of covered business method review of the
`
`patents involved in CBM2014-00161 and CBM2014-00175. See CBM2014-00175
`
`at Paper 14.
`
`Further, the following pending U.S. Patent applications claim the benefit of
`
`U.S. Patent Application No. 10/322,348, which the ’059 patent also claims the
`
`benefit of: U.S. Patent Application No. 14/196,603, filed on March 4, 2014, U.S.
`
`Patent Application No. 14/219,904, filed on March 19, 2014, and U.S. Patent
`
`Application No. 14/219,941 filed on March 19, 2014.
`
`LEAD COUNSEL AND BACK-UP COUNSEL (37 C.F.R. § 42.8(b)(3))
`
`Lead Counsel:
`
`
`
`F. Dominic Cerrito (Reg. No. 38,100)
`
`Contact Information:
`
`Quinn Emanuel Urquhart & Sullivan, LLP
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`51 Madison Avenue, 22nd Floor
`
`New York, NY 10010
`
`Email: nickcerrito@quinnemanuel.com
`
`Telephone: 212-849-7000
`
`
`
`
`
`
`
`
`
`
`
`03387-00001/7207141.1
`
`
`
`Case IPR2015-01816
`Patent 7,895,059
`Patent Owner Mandatory Notices
`
`
`Back-Up Counsel:
`
`John V. Biernacki (Reg. No. 40,511)
`
`Contact Information:
`
`Jones Day
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`North Point
`
`901 Lakeside Avenue
`
`Cleveland, OH 44114
`
`Email: jvbiernacki@jonesday.com
`
`Telephone: 216-586-3939
`
`Back-Up Counsel:
`
`Evangeline Shih (Reg. No. 50,170)
`
`Contact Information:
`
`Quinn Emanuel Urquhart & Sullivan, LLP
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`51 Madison Avenue, 22nd Floor
`
`New York, NY 10010
`
`Email: evangelineshih@quinnemanuel.com
`
`Telephone: 212-849-7000
`
`Back-Up Counsel:
`
`Frank C. Calvosa (Reg. No. 69,064)
`
`Contact Information:
`
`Quinn Emanuel Urquhart & Sullivan, LLP
`
`51 Madison Avenue, 22nd Floor
`
`New York, NY 10010
`
`Email: frankcalvosa@quinnemanuel.com
`
`Telephone: 212-849-7000
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`03387-00001/7207141.1
`
`
`
`Case IPR2015-01816
`Patent 7,895,059
`Patent Owner Mandatory Notices
`
`
`SERVICE INFORMATION
`
`Pursuant to 37 C.F.R. § 42.8(b)(4), please direct all correspondence to lead
`
`and back-up counsel at the above addresses. Patent Owner consents to email
`
`service at the above-specified email addresses.
`
`Date: September 17, 2015
`
`
`Respectfully submitted,
`
`By: /F. Dominic Cerrito (Reg. No. 38,100)/
` F. Dominic Cerrito (Reg. No. 38,100)
` Evangeline Shih (Reg. No. 50,170)
` Frank C. Calvosa (Reg. No. 69,064)
`QUINN EMANUEL URQUHART &
`SULLIVAN LLP
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`Tel: (212) 849-7000
`Fax: (212) 849-7100
`nickcerrito@quinnemanuel.com
`evangelineshish@quinnemanuel.com
`frankcalvosa@quinnemanuel.com
`John V. Biernacki (Reg. No. 40,511)
`JONES DAY
`North Point
`901 Lakeside Avenue
`Cleveland, Ohio 44114
`Tel: (216) 586-3939
`Fax: (216) 579-0212
`jvbiernacki@jonesday.com
`
`Attorneys for Jazz Pharmaceuticals, Inc.
`
`
`
`
`
`03387-00001/7207141.1
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`WOCKHARDT BIO AG
`Petitioner,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`Patent Owner
`
`________________
`
`Case IPR2015-01816
`Patent 7,895,059
`________________
`
`CERTIFICATE OF SERVICE
`
`
`
`
`
`03387-00001/7207141.1
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certify that
`
`MANDATORY NOTICES BY JAZZ PHARMACEUTICALS, INC. and the
`
`attached POWER OF ATTORNEY and 3.73(b) STATEMENT were served on
`
`September 17, 2015 by filing these documents through the Patent Review
`
`Processing System, as well as e-mailing copies to lavogel@duanemorris.com and
`
`PCGallagher@duanemorris.com.
`
`Date: September 17, 2015
`
`03387-00001/7207141.1
`
` Respectfully submitted,
`
`By: /F. Dominic Cerrito (Reg. No. 38,100)/
` F. Dominic Cerrito (Reg. No. 38,100)
` Evangeline Shih (Reg. No. 50,170)
` Frank C. Calvosa (Reg. No. 69,064)
`QUINN EMANUEL URQUHART &
`SULLIVAN LLP
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`Tel: (212) 849-7000
`Fax: (212) 849-7100
`nickcerrito@quinnemanuel.com
`evangelineshish@quinnemanuel.com
`frankcalvosa@quinnemanuel.com
`
`John V. Biernacki (Reg. No. 40,511)
`JONES DAY
`North Point
`901 Lakeside Avenue
`Cleveland, Ohio 44114
`Tel: (216) 586-3939
`Fax: (216) 579-0212
`jvbiernacki@jonesday.com
`
`Attorneys for Jazz Pharmaceuticals, Inc.